JG
AXDX

Joel Greenblatt’s Accelerate Diagnostics AXDX Stock Holding History

Joel Greenblatt’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,094
Closed -$246K – 918
2015
Q1 		$246K Buy
+1,094
New +$229K ﹤0.01% 828

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return

Joel Greenblatt's AXDX Position: Q2 2015 in Review

Joel Greenblatt sold out of Accelerate Diagnostics (AXDX) in Q2 2015, closing a stake of 1,094 shares — an estimated $246K sold.

Joel Greenblatt first reported a position in AXDX in Q1 2015 and held it in 1 quarter. The position peaked at $246K in Q1 2015. 86 funds tracked by Wall St. Rank hold AXDX as of Q2 2015.

  • Joel Greenblatt reported no remaining Accelerate Diagnostics position as of Q2 2015 after selling out during the quarter.
  • Joel Greenblatt sold 1,094 Accelerate Diagnostics shares in Q2 2015, an estimated $246K.
  • Joel Greenblatt first reported a position in Accelerate Diagnostics in Q1 2015 and held it in 1 quarter.
  • Joel Greenblatt's Accelerate Diagnostics position peaked at $246K in Q1 2015.
  • 86 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2015.

Based on Gotham Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.